Evidence map›Paper›PMID 40310503›Full record

ArticleMolecular pharmaceutics2025

Enantiomeric Excess Bupivacaine in a Lavender Oil NLC Tested in a Melanoma Model: Prolonged Release and Anticancer Effect.

Gabriela Geronimo, Gustavo H Rodrigues da Silva, Ludmilla D de Moura, Fabíola V de Carvalho, Talita C Mendonça, Laura B Olivo, Bibiana Verlindo de Araújo, Teresa C Dalla Costa, Luccas Lavareze, Fernanda V Mariano and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gabriela GeronimoDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.
Gustavo H Rodrigues da SilvaBrazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials, Campinas, SP 13083-970, Brazil.ORCID 0000-0001-7377-8532
Ludmilla D de MouraDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.
Fabíola V de CarvalhoDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.
Talita C MendonçaDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.
Laura B OlivoPharmaceutical Sciences Graduate Program, Faculty of Pharmacy, Federal University of Rio Grande do Sul─UFRGS, Porto Alegre, RS 90610-000, Brazil.
Bibiana Verlindo de AraújoPharmaceutical Sciences Graduate Program, Faculty of Pharmacy, Federal University of Rio Grande do Sul─UFRGS, Porto Alegre, RS 90610-000, Brazil.
Teresa C Dalla CostaPharmaceutical Sciences Graduate Program, Faculty of Pharmacy, Federal University of Rio Grande do Sul─UFRGS, Porto Alegre, RS 90610-000, Brazil.
Luccas LavarezeDepartment of Pathology, Faculty of Medical Sciences, UNICAMP, Campinas, SP 13083-888, Brazil.
Fernanda V MarianoDepartment of Pathology, Faculty of Medical Sciences, UNICAMP, Campinas, SP 13083-888, Brazil.
Eneida de PaulaDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas─UNICAMP, Campinas, SP 13083-862, Brazil.ORCID 0000-0003-4504-5723

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have highlighted the potential of local anesthetics (LA) as adjuvants in cancer treatment, specifically by increasing survival rates when used in surgical excisions. However, the clinical use of LA is restricted due to their systemic toxicity. The development of drug delivery systems could address this issue and advance the utilization of these molecules. In this research, we explored the pharmacokinetics (using microdialysis probes) and antitumor properties of a nanostructured lipid carrier (NLC) formulation containing the commercially available enantiomeric excess form of bupivacaine (BVC

Indexed as

Antineoplastic AgentsBupivacaineMelanomaOils, VolatilePlant OilsAnesthetics, LocalAnimalsCell Line, TumorDelayed-Action PreparationsDrug CarriersDrug Delivery SystemsFemaleHumansLavandulaLipidsMaleAnesthetics, LocalAntineoplastic AgentsBupivacaineDelayed-Action PreparationsDrug Carrierslavender oilLipidsOils, VolatilePlant Oilsbupivacainedrug deliverylavender oilmelanomananostructured lipid carriers

Identifiers

PMID40310503
PMCPMC12135038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.